Auro Laboratories share price, P/E, ROE & financials

Auro Laboratories (BSE: AUROLAB) had a P/E of 30.3× on 6 Nov 2026, above the industry P/E of 28.7×, and the shares are 28% below their 52-week high. Its ROCE of 9.5% is the second-lowest among the 7 largest Drug Manufacturers (Specialty & Generic) peers, and sales fell 16% a year over 3 years while net profit grew 13%. Debt is 1.37× equity. It is a small-cap company with a market cap of ₹142 Cr, ranked 106th of 154 Drug Manufacturers (Specialty & Generic) companies by market cap; the shares rose 15% over the past year.

As of 6 Nov 2026Prices are delayed about 15 minutes; fundamentals are from the quarter ended Jun 2026.How we calculate this

past year

Open: ₹224.75
Day high: ₹231.20
Day low: ₹217.00
Prev. close: ₹224.80
Volume: 665

Health check

4 fair · 2 to check

ReturnsIn line
+15.0% over a year, better than 3 of 7 peers.
Price tagIn line
P/E 30.3 vs industry 28.7.
GrowthSteady
Sales −16.2%, profit +13.1% a year over 3 years.
ProfitabilityWeak
ROCE 9.5% vs peer median 17.9%.
Balance sheetFair
Debt 1.37× equity, interest covered 2.2×, Piotroski 7 of 9.
Red flags2 to check
Return on equity is low at 7.9%.

Compared with 7 industry peers. Computed from reported figures. Educational, not a recommendation.

Drug Manufacturers - Specialty & Generic

153 listed peers. Screen the industry

Small cap

₹142 Cr, #106 of 154 in its industry by size.

Market sensitivity

Measuring against the NIFTY 50…

Key metrics

Last 12 months to Jun 2026: sales ₹37 Cr · profit ₹5 Cr

Market cap: ₹142 Cr; Small cap
P/E: 30.3; Industry 28.7
Price to book: 3.06; Peers 4.99
Dividend yield: 0.00%
ROE: 7.9%; Peers 14.7%
ROCE: 9.5%; Peers 17.9%
Debt to equity: 1.37; Debt ₹63 Cr
EPS (TTM): ₹7.52
OPM (TTM): 35.4%; Net margin 12.8%
Sales growth: +216.1%; Latest quarter vs a year ago
Profit growth: n/a; Year-ago quarter not reported
Price to sales: 3.86; EV/EBITDA 15.4

Strengths

Quarterly sales up 216.1% on a year ago.
Positive operating cash flow in each of the last 4 years.

Risks to check

Return on equity is low at 7.9%.
Interest coverage of only 2.7×.

Derived automatically from reported figures. Not a recommendation.

About Auro Laboratories

Auro Laboratories Limited manufactures and sells active pharmaceutical ingredients (APIs), intermediates, and generic formulations in India and internationally. It offers antihistamine; muscle relaxant; diuretic; iron deficiency; anti-diabetic; anti-fungal, ulcer, malaria, and inflammatory; iodine supplement; analgesics; antacids; potassium and sodium iodide; and microcrystalline cellulose. The company also provides specialty chemicals comprising…

Headquarters: Mumbai
Employees: 78
Sector: Healthcare
ISIN: INE292C01011
Website: aurolabs.com

Price range

52 weeks

₹159.00₹317.00

Today

₹217.00₹231.20

Avg volume (3M): 4.3K
1-year return: plus 15.0%
From 52-week high: minus 28.2%

Peers · Drug Manufacturers - Specialty & Generic

Compare with peers Screen the whole industry

Company
SUNPHARMASun Pharmaceutical Industries	1,860.00	plus 1.69%	4,46,276	40.7	4.99	17.9%	13.1%	28.2%	10.4%	10.6%	0.86%	plus 8.2%
DIVISLABDivi's Laboratories	10,320.50	plus 1.78%	2,73,977	93.6	16.35	19.0%	16.2%	34.9%	11.0%	12.1%	0.29%	plus 49.0%
TORNTPHARMTorrent Pharmaceuticals	4,750.00	plus 0.85%	1,80,675	80.2	9.83	9.1%	15.7%	33.7%	13.3%	20.2%	0.80%	plus 31.7%
LAURUSLABSLaurus Labs	2,340.00	minus 0.26%	1,26,433	94.4	20.86	19.5%	24.0%	30.4%	3.8%	4.0%	0.09%	plus 138.6%
ZYDUSLIFEZydus Lifesciences	1,197.90	plus 0.41%	1,19,491	28.6	4.29	19.0%	14.7%	26.2%	16.5%	37.0%	0.08%	plus 22.8%
DRREDDYDr. Reddy's Laboratories	1,373.00	plus 0.51%	1,14,462	40.9	2.96	14.2%	7.3%	15.9%	11.0%	−1.7%	0.58%	plus 13.8%
CIPLACipla	1,411.00	plus 0.49%	1,13,993	39.4	3.22	14.9%	8.3%	17.3%	7.2%	11.5%	0.92%	minus 6.6%
AUROLABAuro Laboratories	227.60	plus 1.25%	142	30.3	3.06	9.5%	7.9%	35.4%	−16.2%	13.1%	0.00%	plus 15.0%
Median of 7 peers	–	0.51%	1,26,433	40.9	4.99	17.9%	14.7%	28.2%	11.0%	11.5%	0.58%	22.8%

Quarterly results

Consolidated, ₹ crore

SalesSelect a row below to chart it

Jun 25	Sep 25	Dec 25	Mar 26	Jun 26
2.8	8.8	9.4	9.8	8.8
2.7	6.5	5.3	6.5	5.5
0	2.4	4.1	3.3	3.3
1.2%	26.7%	43.3%	33.8%	37.7%
0.4	1	0.2	0.7	0.1
0.3	1	1.5	1.5	1.4
0.3	0.7	1	0.9	0.9
–	–	–	−0.1	–
−0.1	1.7	1.7	1.5	1.1
–	58.4%	−12.3%	33.3%	–
−0.1	0.7	2	1	1.1
-0.17	1.15	3.13	1.56	1.68

Profit & loss

Yearly, ₹ crore

Sales CAGR 3Y: −16.2%
Profit CAGR 3Y: +13.1%
EPS CAGR 3Y: +13.1%
ROE: 7.9%

Net profitSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
52.3	53.6	19.1	30.7
–	+2.6%	minus 64.3%	+60.7%
47.9	43	15.7	20.1
4.4	10.7	3.4	10.7
8.4%	19.9%	17.8%	34.7%
0.9	1.5	0.6	1.3
0.8	0.7	1	4
1.1	1.1	1.1	2.8
–	–	–	−0.3
3.4	10.3	1.9	4.8
29.1%	24.7%	2.2%	26.5%
2.4	7.8	1.8	3.5
–	+219.1%	minus 76.4%	+92.1%
3.92	12.50	2.95	5.67

Forecast

Your assumptions, not a prediction

Balance sheet

At each financial year end, ₹ crore

Total assetsSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
6.2	6.2	6.2	6.2
28	35.7	36.7	40.1
6.4	26.2	42.7	63.3
15.4	17.5	13.4	11.4
56	85.7	99.1	121
20.3	54.8	77.5	89.7
7.7	32.7	56.5	14.5
0	0	0	0
4.6	1.5	0	1.4
23.3	−3.3	−35	15.6
56	85.7	99.1	121

Cash flow

Yearly, ₹ crore

Cash from operationsSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
3.3	18.8	5	2.1
−5.1	−38.7	−23.7	−14.8
−8.2	19.1	17.7	14
−10	−0.8	−1	1.4
−4.1	−35.6	−23.8	−15.1
−0.8	−16.8	−18.8	−13

Shareholding pattern

This company is listed only on BSE, so there’s no NSE category split. See Major shareholders below for the named holders.

Major shareholders

BSE filing

Filings & events

News

No recent news coverage found.

My notes

Private to you